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DISCUSSION
Unidentified speaker . . . Based on the title of your abstract,
your original idea was to present primary versus secondary DVT
and then now you introduce this term of inpatient and outpatient
DVT which is a new term and it does not exist in the CEEP
classification or any type of classification that we use, because it is
difficult to compare primary to secondary.
Dr Peter Henke (Ann Arbor, Mich). Right.
Unidentified speaker. So my question is, did you see a
difference in bilaterality, and I am thinking of the May-Turner
syndrome, in patients who had inpatient or outpatient or primary
or secondary DVT?
DrHenke.Thank you verymuch for your comments. Primary
DVT versus recurrent – these were all primary DVT in the sense
that the patients had no documented history of a previous venous
thromboembolism or DVT, so they are all primary in that sense.
But somewhat arbitrarily we wanted to try to define those who had
it with no discernible proximate risk factor such as surgery or
trauma versus those who did not. We did find that in the inpatients
the bilaterality of DVT was more common. One of our first
hypotheses when we were coming up with this study was that to try
to discern if early and rapid anticoagulation would prevent long-
term postthrombotic syndrome, you cannot do that ethically.
Once it is diagnosed you have to treat it, so you can’t wait or
determine a certain amount of time before giving heparin. We
thought patients with an inpatient development of DVT might be
more rapidly treated than patients who come in, in part because of
delays or time in the emergency room and that type of thing. The
big result would be the survey in the postthrombotic syndrome,
trying to delineate that but unfortunately the the survey results
were just so poor we couldn’t do it validly.
Unidentified speaker. Could you comment on the infre-
quent use of effective prophylaxis in relatively high risk patients
______ given the published guidelines and the depth of experience
that Michigan has in DVT? It seems at odds with reality.
Dr Henke. Right. When I looked at that, I thought, boy,
that’s a low use of prophylaxis, and the thing we do not know is the
denominator of all the patients who were treated similarly over that
same period of time who did not have a DVT. This is a selected
group in a sense that they all had DVT as inpatients and their use of
prophylaxis was low. Since the time that this has come about, since
about 2004, 2005, we now have established hospital wide guide-
lines from the office of clinical affairs and Dr. Darrell Campbell
based on Joe Caprini’s risk factor score sheet and the ______
consensus guidelines. It is something that we are going to measure
as well. All patients who get admitted now get a score sheet to
make sure they at least address the risk for ______.
Unidentified speaker. Only 64% of the patients received
Coumadin _______ Can you comment on that? _______
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DrHenke. The one thing I realized, of course late, was that we
did not define exactly who and who did not get a filter. Some of the
inpatients did have bleeding events which I think had them stop their
Coumadin use and I assume they got filter, but I do not know. I will
have to look back at the charts for that.WhyCoumadin use conferred
a decreased risk of mortality – again it may be a surrogate that patients
whowere able to take Coumadin and not have complications had less
risk of death, whereas those who could not take Coumadin perhaps
were so ill overall and such high risk of bleeding that that again is a
surrogate for mortality or significant illness.
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